Researchers at Colorado State University have developed an enhanced tissue-staining technique called Amplified Immunohistochemistry (AMP-IHC) that reveals hidden disease-causing prions while preserving clear cellular structures. By combining standard antibody staining with catalytic signal amplification, AMP-IHC drastically improves visual signal intensity in low-burden tissue samples. This increased sensitivity enhances detection of prions within lymphoid follicles, allowing diagnosticians to identify and quantify infected follicles more effectively, particularly in tissues with minimal prion accumulation or during early stages of Chronic Wasting Disease (CWD). The technique also enabled scientists to detect CWD prions within uterine glands at the maternal-fetal interface, providing direct visual evidence that the disease can be transmitted in utero from mother to offspring. Because AMP-IHC integrates seamlessly into existing diagnostic laboratory workflows, it has the potential to strengthen CWD surveillance, improve diagnostic confidence, and advance research into disease pathogenesis and transmission.
Chronic Wasting Disease (CWD) and related transmissible spongiform encephalopathies pose severe ecological and economic threats, yet diagnostic surveillance is limited by traditional testing methods. Standard tools such as conventional immunohistochemistry (IHC) and ELISA frequently fail to detect low concentrations of aberrant prion proteins (〖”PrP” 〗^”CWD” ) during subclinical or early-stage infections. Conversely, ultrasensitive molecular amplification assays (such as RT-QuIC or PMCA) can identify minute prion seeding activity but lack the spatial resolution required to pinpoint cellular localization within host tissues. AMP-IHC bridges this critical gap by combining molecular-level detection sensitivity with histological context to resolve subtle target accumulation within intact tissue microenvironments.
AMP-IHC enhances conventional immunohistochemistry workflows by coupling primary antibody binding with tyramide signal amplification (TSA) and biotin-streptavidin-horseradish peroxidase (HRP) detection systems. Following routine tissue preparation, proteinase K digestion, antigen retrieval, and primary antibody incubation, a biotinylated tyramide substrate undergoes localized catalytic deposition via HRP. This generates high-density signal precipitation specifically at target antigen sites while minimizing non-specific background staining, enabling visualization of low-abundance 〖”PrP” 〗^”CWD” deposits across central nervous system, lymphoid, and reproductive tissues that remain undetected under standard IHC protocols.
In comparative evaluations across lymphoid tissues (retropharyngeal lymph nodes, RAMALT, and tonsils) from naturally infected white-tailed deer, AMP-IHC increased the proportion of detectable 〖”PrP” 〗^”CWD” -positive follicles by 11.9% to 57.1% (mean increase of 30.7 ± 13.4%) relative to conventional IHC without generating non-specific background in uninfected controls. Specific sample gains included retropharyngeal lymph node follicle positivity rising from 2.9% to 42.7% (Δ=39.8%) and RAMALT positivity jumping from 14.3% to 71.4% (Δ=57.1%). Furthermore, when applied to the maternal-fetal interface in experimentally infected deer models, AMP-IHC detected localized prion accumulation within the uterine glandular epithelium and lumen in 50% (4 of 8) of infected dams, whereas conventional IHC yielded 0% detection (0 of 8) across matched tissue blocks.
• Superior Diagnostic Sensitivity: Significantly increases signal intensity and visualization of low-abundance prions during subclinical or early-stage infections without introducing non-specific background.
• Preserved Histomorphology: Retains precise spatial and cellular localization of targets within intact anatomical structures, overcoming the loss of tissue architecture inherent to cell-free amplification methods.
• Quantitative Follicle Resolution: Substantially expands detectable positive lymphoid follicles by 11.9% to 57.1% in low-burden tissue samples.
• Seamless Laboratory Adoption: Builds directly upon existing USDA-approved IHC infrastructure, requiring minimal protocol adjustments or equipment outlay for accredited diagnostic laboratories.
• Mechanistic Discovery Capabilities: Enables clear mapping of cellular disease transmission pathways, such as identifying prion accumulation within uterine glands responsible for nutrient transfer to the developing fetus.
• Wildlife Disease Surveillance: High-throughput screening and early-stage monitoring of Chronic Wasting Disease in wild cervid populations (e.g., white-tailed deer, elk, moose).
• Veterinary Diagnostic Laboratories: Enhanced confirmatory testing for regulatory CWD herd certification programs and low-signal biopsy samples.
• Maternal-Fetal Transmission Research: Investigating vertical transmission mechanisms, early target tissues, and reproductive pathways in cervids and livestock.
• Prion & Amyloid Pathology Mapping: Fine-grained cellular localization of low-abundance misfolded proteins in veterinary and comparative medicine research.
Available for Exclusive Licensing
Available for Collaboration or Funding
TRL: 5
US Provisional Patent
Candace Mathiason
Jesse Cole
Steve Foster
Steve.foster@colostate.edu
970-491-7100